latest news releases from the newsroom
Rumors of Stock Offering Quashed by Zanett CFO
NEW YORK, July 31, 2007 (PRIME NEWSWIRE) -- Zanett Inc. (Nasdaq:ZANE) a leading information technology (IT) consulting firm serving Fortune 500 corporations, mid-market companies, and classified government agencies involved in Homeland Defense and Homeland Security, today announced that there is no validity in the rumor that Zanett is contemplating an equity offering.
Famed Filmmaker & Actor, Eric Schaeffer Releases Memoir, I Can't Believe I'm Still Single...
NEW YORK, July 31, 2007 (PRIME NEWSWIRE) -- Eric Schaeffer, filmmaker/actor, released his latest artistic endeavor, a memoir entitled: I Can't Believe I'm Still Single -- Sane, slightly neurotic (but in a sane way) filmmaker into yoga, bad reality TV, too much chocolate, and a little kinky sex seeks smart, emotionally evolved...oh hell, at this point anyone who'll let me watch football. (336 pages trade paperback, original $14.95, ISBN: 1-5658-337-0)
HealthSport Launches Next Generation Fix Hangover Strips
AMHERST, N.Y., July 31, 2007 (PRIME NEWSWIRE) -- HealthSport, Inc. (HSPO) announced today the commencement of production of the latest addition to its offering of edible thin strip products, Fix(tm) Hangover Strips (http://www.fixstrips.com) -- a nutritional supplement formulated to provide rapid relief from hangover symptoms. A creation of HealthSport's wholly-owned subsidiary, Cooley Nutraceuticals, Inc., the new product utilizes edible thin film delivery technology developed by InnoZen, Inc. of Woodland Hills, CA, another HealthSport subsidiary and the manufacturer of Fix Hangover Strips.
Generex Biotechnology Corp.
The International Journal of Cancer Publishes Studies on the Anti-Cancer Activity of Generex Biotechnology's Immunotherapeutic Vaccine
WORCESTER, Mass., July 31, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) announced today publication in the peer-reviewed International Journal of Cancer (published online Jul 16, 2007) of studies demonstrating the anti-tumor activity of its novel Ii-Key/HER-2/neu immunotherapeutic vaccine as well as mechanistic explanations for the enhancements observed using this proprietary vaccine. The studies were conducted as part of a collaboration between the Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece and Antigen Express, Inc., the immunotherapeutic subsidiary of Generex. The article was authored by Ioannis F. Voutsas, Angelos D. Gritzapis, Louisa G. Mahaira, Maria Salagianni, Eric von Hofe, Nikoletta L. Kallinteris, and Constantin N. Baxevanis.